News
OncClub
All Oncology News
Clinical Trials in Focus
Watch
Expert Conversations
Shows & Podcasts
News & Analysis
Conferences
Conference Coverage
Conference Listing
Events
Giants of Cancer Care
CME/CE
Scientific Interchanges
State of the Science Summit
National Fellows Forum
Webinars
More
Partners
Publications
All Publications
Supplements
Resources
Consensus Viewpoints
OncLive App
Interactive Tools
Sponsored
Biomarker Consortium
Subscribe
Scout
My Account
Scout
News
Watch
Conferences
Events
Partners
Publications
Resources
Biomarker Consortium
Subscribe
AI for Oncology
Biosimilars
Brain Cancer
Breast Cancer
HER2+ Breast Cancer
CAR T-Cell Therapy
Disparities in Cancer Care
Gastrointestinal Cancer
Pancreatic Cancer
Hepatocellular Carcinoma
Gastric Cancer
Colorectal Cancer
Genitourinary Cancers
Urothelial Cancer
Prostate Cancer
Global Oncology
Graft-vs-Host Disease
Gynecologic Oncology
Ovarian Cancer
Head & Neck Cancers
Hematologic Oncology
Chronic Lymphocytic Leukemia
Non-Hodgkin Lymphoma
Mantle Cell Lymphoma
Multiple Myeloma
Myeloproliferative Neoplasms
Immuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Oncology Business Management
Pediatric Oncology
Precision Medicine in Oncology®
Sarcomas
Supportive Care
Choose Specialty
Spotlight -
The OncLive Insider app is live!
|
CME Opportunities
Advertisement
Eugene Feit
Advertisement
Articles by Eugene Feit
The Downside to Beating the Odds
By
Eugene Feit
March 4th 2011
By now, I am supposed to be dead.
Advertisement
Latest Updated Articles
The Downside to Beating the Odds
March 4th 2011
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daraxonrasib for Metastatic Pancreatic Ductal Adenocarcinoma
2
Dr Reiss Binder on the FDA Approval of Daraxonrasib for Metastatic PDAC
3
ASCO Issues Warning Regarding Ifosfamide Shortage for Cancer Care
4
Dr Ayanambakkam on the Safety of Darlifarnib Plus Cabozantinib in RCC KD
5
Dr Borate on Efficacy Data for Shorter Venetoclax-Plus-Azacitidine Dosing in AML